Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques

Journal of Virology

Volumn 74, Issue 6, 2000, Pages 2960-2965

  Ourmanov, Ilnour ^a   Bilska, Miroslawa ^b   Hirsch, Vanessa M ^a   Montefiori, David C ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; POL PROTEIN; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; IMMUNIZATION; MACACA; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV ENVELOPE PROTEIN GP120; HUMANS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; TUMOR CELLS, CULTURED; VACCINES, DNA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL VACCINES;

EID: 0033995525     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.6.2960-2965.2000     Document Type: Article

References (50)

1. Belshe, R. B., G. J. Gorse, M. J. Mulligan, T. G. Evans, M. C. Keefer, J.-L. Excler, A.-M. Duliege, J. Tartaglia, J. McNamara, H. Kai-Lin, D. Montefiori, and K. Weinhold. 1998. Rapid induction of HIV-1 immune responses by canarypox (ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers. AIDS 12:2407-2415.
2. Bloom, B. R. 1998. The highest attainable standard: ethical issues in AIDS vaccines. Science 279:186-188.
3. Burton, D. R., and D. C. Montefiori. 1997. The antibody response in HIV-1 infection. AIDS 11(Suppl. A):S87-S98.
4. Clements, J. E., R. C. Montelaro, M. C. Zink, A. M. Amedee, S. Miller, A. M. Trichel, B. Jagerski, D. Hauer, L. N. Martin, R. P. Bohm, and M. Murphey-Corb. 1995. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:2737-2744.
5. SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177:1230-1246.
6. Cooney, E. L., M. J. McElrath, L. Corey, S.-L. Hu, A. C. Collier, D. Arditti, M. Hoffman, R. W. Coombs, G. E. Smith, and P. D. Greenberg. 1993. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. USA 90:1882-1886.
7. Excler, J.-L., and S. Plotkin. 1997. The prime-boost concept applied to HIV preventive vaccines. AIDS 11(Suppl. A):S127-S137.
8. Foresman, L., F. Jia, Z. Li, C. Wang, E. B. Stephens, M. Sahni, O. Narayan, and S. V. Joag. 1998. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res. Hum. Retrovir. 14:1035-1043.
9. Gauduin, M.-C., P. W. H. I. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:1389-1393.
10. Gould, E. A., A. Buckley, A. D. T. Barret, and N. Cammack. 1986. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67:591-595.
11. Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. C. Keefer, D. P. Bolognesi, L. Corey, D. M. Stablein, J. R. Esterlitz, S.-L. Hu, G. E. Smith, P. E. Fast, and W. C. Koff. 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naïve adults. J. Infect. Dis. 167:533-537.
12. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. J. Engl. J. Med. 333:1331-1339.
13. Haigwood, N. L., A. Watson, W. F. Sutton, J. McClure, A. Lewis, J. Ranchalis, B. Travis, G. Voss, N. L. Letvin, S.-L. Hu, V. M. Hirsch, and P. R. Johnson. 1996. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:107-114.
14. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271: 324-328.
15. Heilman, C. A., and D. Baltimore. 1998. HIV vaccines - where are we going? Nat. Med. 4:532-534.
16. Hirsch, V., D. Adger-Johnson, B. Campbell, S. Goldstein, C. Brown, W. R. Elkins, and D. C. Montefiori. 1997. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J. Virol. 71:1608-1620.
17. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson, 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
18. Hirsch, V. M., R. A. Olmsted, M. Murphey-Corb, R H. Purcell, and P. R. Johnson. 1989. An African non-human primate lentivirus (SIVsm) closely related to HIV-2. Nature 339:389-392.
19. Hirsch, V. M., P. M. Zack, A. P. Vogel, and P. R. Johnson. 1991. Simian immunodeficiency virus infection of macaques: pathogenesis of end-stage disease in characterized by high levels of proviral DNA in tissues. J. Infect. Dis. 163:976-988.
20. Hu, S.-L. 1996. Recombinant subunit vaccines against primate lentiviruses. AIDS Res. Hum. Retrovir. 12:451-453.
21. Hu, S.-L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton. and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
22. Hu, S.-L., P. N. Fults, H. M. McClure, J. W. Eichberg, E. K. Thomas, J. Zarling, M. C. Singhal, S. G. Kosowski, R. B. Swenson, D. C. Anderson, and G. Todaro. 1987. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 328:721-723.
23. Johnson, P. R., D. C. Montefiori, S. Goldstein, T. E. Hamm, J. Zhou, S. Kitov, N. L. Haigwood, L. Misher, W. T. London, J. L. Gerin, A. Allison, R. H. Purcell, R. M. Chanock, and V. M. Hirsch, 1992. Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. AIDS Res. Hum. Retrovir. 8:1501-1505.
24. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
25. Langlois, A. J., R. C. Desrosiers, M. G. Lewis, V. N. Kewalramani, D. R. Littman, J. Y. Zhou, K. Manson, D. P. Bolognesi, M. S. Wyand, and D. C. Montefiori. 1998. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol. 72:6950-6955.
26. Lefrancois, L. 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J. Virol. 51:208-214.
27. Letvin, N. L. 1998. Progress in the development of an HIV-1 vaccine. Science 280:1875-1880.
28. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, Y. Lu, M. L. Robb, H. Katinger, and D. L. Birx. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
29. Mathews, J. H., J. T. Roehrig, and D. W. Trent. 1985. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J. Virol. 55:594-600.
30. Means, R. E., T. Greenough, and R. C. Desrosiers. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71:7895-7902.
31. Montefiori, D. C. 1997. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin. Immunopathol. 18:371-390.
32. Montefiori, D. C., T. W. Baba, A. Li, M. Bilska, and R. M. Ruprecht. 1996. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239Δ3 in adult and infant rhesus monkeys. J. Immunol. 157:5528-5535.
33. Montefiori, D. C., and T. G. Evans. Toward an HIV-1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res. Hum. Retrovir., in press.
34. Moog, C. H., J. A. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following ini-tial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
35. Moore, J. P., and J. Binley. 1998. Envelope's letters boxed into shape. Nature 393:630-631.
36. Mozdzanowska, K., M. Furchner, G. Washko, J. Mozdzanowski, and W. Gerhard. 1997. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71:4347-4355.
37. Nakanaga, K., K. Yamanouchi, and K. Fujiwara. 1986. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J. Virol. 59:168-171.
38. Nara, P. L., and R. Garrity. 1998. Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 16:1780-1787.
39. Ourmanov, I., C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch. 2000. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in Macaques challenged with pathogenic SIV. J. Virol. 74:2740-2751.
40. Pellegrin, I., E. Legrand, D. Neau, P. Bonol, B. Masquelier, J.-L. Pellegrin, J.-M. Ragnaud, N. Bernard, and H. J. A. Fleury. 1996. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J. Acquir. Immune Defic. Syndr. 11:438-147.
41. Pialoux, G., J.-L. Excler, Y. Rivière, G. Gonzalez-Canali, V. Feuillie, P. Couland, J.-C. Gluckman, T. J. Matthews, B. Meignier, M.-P. Kieny, P. Gonnet, I. Diaz, C. Méric, E. Paoletti, J. Tartaglia, H. Salomon, and S. Plotkin. 1995. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retrovir. 11: 373-381.
42. Pilgrim, A. K., G. Pantaleo, O. J. Cohen, L. M. Fink, J. Y. Zhou, J. T. Zhou, D. P. Bolognesi, A. S. Fauci, and D. C. Montefiori. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection. J. Infect. Dis. 176:924-932.
43. Pincus, S. H., R. Cole, R. Ireland, F. McAtee, R. Fujisawa, and J. Portis. 1995. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J. Virol. 69:7152-7158.
44. Schmaljohn, A. L., E. D. Johnson, J. M. Dalrymple, and G. A. Cole. 1982. Nonneutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature (London) 297:70-72.
45. Seth, A., I. Ourmanov, M. J. Kuroda, J. E. Schimtz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin. 1998. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc. Natl. Acad. Sci. USA 95:10112-10116.
46. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M. W. Cho, and M. A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204-210.
47. Tyler, D. S, H. K. Lyerly, and K. J. Weinhold. 1989. Anti-HIV-1 ADCC: a minireview. AIDS Res. Hum. Retrovir. 5:557-563.
48. Van Rompay, K. K. A., C. J. Berardi, S. Dillard-Telm, R. P. Tarara, D. R. Canfield, C. R. Valverde, D. C. Montefiori, K. Stefano-Cole, R. C. Montelaro, C. J. Miller, and M. L. Marthas. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177:1247-1259.
49. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
50. Zhang, J.-Y., L. N. Martin, E. A. Watson, R. C. Montelaro, M. West, L. Epstein, and M. Murphey-Corb. 1988. Simian immunodeficiency virus/Delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigcnemia. J. Infect. Dis. 158:1277-1286.